Format

Send to

Choose Destination
Res Microbiol. 2018 Nov;169(9):540-542. doi: 10.1016/j.resmic.2018.05.001. Epub 2018 May 16.

Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.

Author information

1
Eliava Phage Therapy Center, Tbilisi, Georgia. Electronic address: Phage_therapy@pha.ge.
2
Eliava Phage Therapy Center, Tbilisi, Georgia.
3
Eliava Institute of Bacteriophages, Microbiology, Virology, Tbilisi, Georgia.
4
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany.

Abstract

Respiratory infections can lead to serious complications in CF patients, especially when infected with antibiotic resistant bacteria. Alternative treatments for these infections are being sought out to help address this problem. We present a clinical case of a cystic fibrosis (CF) patient, with multi-drug resistant (MDR) Achromobacter xylosoxidans chronic lung infection who was successfully managed with bacteriophage therapy.

KEYWORDS:

Achromobacter xylosoxidans; Antibiotic resistance; Bacteriophage; Cystic fibrosis; Phage therapy; Respiratory infection

PMID:
29777836
DOI:
10.1016/j.resmic.2018.05.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center